NCT07185321

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

An Open-Label, Phase 1 Study to Investigate the Absolute Bioavailability and the Absorption, Metabolism, and Excretion of [14C]-Mosliciguat in Healthy, Adult Males

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Pulmovant, Inc. · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	Mosliciguat	Dose level for inhalation
DRUG	14C mosliciguat	Dose level
DEVICE	Dry Powder Inhaler	Dry powder inhaler for mosliciguat

Timeline

• Start date: 2025-06-10
• Primary completion: 2026-03-01
• Completion: 2026-05-01
• First posted: 2025-09-22
• Last updated: 2025-09-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study